SCHEMBL559960

SCHEMBL559960

Nc1cc([C@@H]2CNC(=O)C2)c([N+](=O)[O-])cc1Cl

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.45
MAPT P10636 5/20 0.44
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
LMNA P02545 2/20 0.39
GALR3 O60755 1/20 0.36
THRB P10828 1/20 0.36
CYP3A4 P08684 1/20 0.36
MTNR1A P48039 2/20 0.36
PDE7A Q13946 1/20 0.34
TSHR P16473 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
SLC6A4 P31645 1/20 0.32
PDE4A P27815 3/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C19 P33261 1/20 0.32
PDE4B Q07343 1/20 0.32
PDE4C Q08493 1/20 0.32
PDE4D Q08499 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16971144 0.78 MAPK1 (0.45) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL560648 0.78 MAPK1 (0.43) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL559945 0.78 MTNR1A (0.39) ALDH1A1KMT2AMEN1MTNR1ATSHR
SCHEMBL6672459 0.77 MAPT (0.47) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL559806 0.75 PDK1 (0.36) ALDH1A1MAPT
SCHEMBL560675 0.73 ALDH1A1 (0.48) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL31570534 0.73 MAPT (0.48) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL559712 0.69 MTNR1A (0.48) ALDH1A1KMT2ACYP3A4MTNR1ATSHR
SCHEMBL559921 0.69 PDE4A (0.52) ALDH1A1MAPTKMT2AMEN1LMNA
SCHEMBL16971204 0.69 MTNR1A (0.34) ALDH1A1MAPTLMNAMTNR1ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8344028-B2 Gamma-amino-butyric acid derivatives as GABAB receptor ligands XENOPORT, INC. (US) 2013-01-01 US disclosed
EP-2419401-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS XenoPort, Inc. (US) 2012-02-22 EP disclosed
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2012-02-09 US disclosed
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. 2010-10-21 US disclosed
WO-2010120370-A2 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS XENOPORT, INC. (US) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267676-A1 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 ALDH1A1 1314/4885MAPT 1142/4885KMT2A 3550/4885
US-20120035139-A9 GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAB RECEPTOR LIGANDS GABRB2, GABRB1, GABRB3 ALDH1A1 1314/4885MAPT 1142/4885KMT2A 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.